open access

Vol 13, No 3 (2020)
Guidelines / Expert consensus
Published online: 2020-12-03
Get Citation

Emicizumab (Hemlibra®) in hemophilia A patients with inhibitors against factor VIII — guidelines of the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine

Jerzy Windyga, Krzysztof Chojnowski, Anna Klukowska, Paweł Łaguna, Magdalena Łętowska, Andrzej Mital, Wojciech Młynarski, Jacek Musiał, Jacek Treliński, Anetta Undas, Tomasz Urasiński, Joanna Zdziarska, Maria Podolak-Dawidziak
DOI: 10.5603/JTM.2020.0006
·
Journal of Transfusion Medicine 2020;13(3):165-175.

open access

Vol 13, No 3 (2020)
GUIDELINES
Published online: 2020-12-03

Abstract

In this document, the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine presents the guidelines for the use of emicizumab. Emicizumab (Hemlibra®, F. Hoffmann — La Roche, Basel, Switzerland) has been licensed for use in the European Union in 2018. In Poland, this medicinal product has been available for patients with congenital hemophilia A and inhibitors against factor VIII since March 2020. This paper is a supplement to the 2017 guidelines for management of patients with haemophilia A and B and inhibitors against factor VIII or IX.

Abstract

In this document, the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine presents the guidelines for the use of emicizumab. Emicizumab (Hemlibra®, F. Hoffmann — La Roche, Basel, Switzerland) has been licensed for use in the European Union in 2018. In Poland, this medicinal product has been available for patients with congenital hemophilia A and inhibitors against factor VIII since March 2020. This paper is a supplement to the 2017 guidelines for management of patients with haemophilia A and B and inhibitors against factor VIII or IX.

Get Citation

Keywords

emicizumab; haemophilia A; inhibitor; prophylaxis; bleeding; guidelines; Poland; factor VIII; by-passing agents; rFVIIa; aPCC

About this article
Title

Emicizumab (Hemlibra®) in hemophilia A patients with inhibitors against factor VIII — guidelines of the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine

Journal

Journal of Transfusion Medicine

Issue

Vol 13, No 3 (2020)

Article type

Guidelines / Expert consensus

Pages

165-175

Published online

2020-12-03

DOI

10.5603/JTM.2020.0006

Bibliographic record

Journal of Transfusion Medicine 2020;13(3):165-175.

Keywords

emicizumab
haemophilia A
inhibitor
prophylaxis
bleeding
guidelines
Poland
factor VIII
by-passing agents
rFVIIa
aPCC

Authors

Jerzy Windyga
Krzysztof Chojnowski
Anna Klukowska
Paweł Łaguna
Magdalena Łętowska
Andrzej Mital
Wojciech Młynarski
Jacek Musiał
Jacek Treliński
Anetta Undas
Tomasz Urasiński
Joanna Zdziarska
Maria Podolak-Dawidziak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl